Allogene Therapeutics (ALLO) Analyst & Key Data

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

19

Hold

10

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.78

Median Target+261.24%

$6.43

Potential upside vs current price

DCF Value-108.70%

-$0.15

Potential downside vs current price

Current Stock Price

$1.78

Median Target+261.24%

$6.43

Potential upside vs current price

DCF Value-108.70%

-$0.15

Potential downside vs current price

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

19

Hold

10

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.78

Median Target+261.24%

$6.43

Potential upside vs current price

DCF Value-108.70%

-$0.15

Potential downside vs current price

Current Stock Price

$1.78

Median Target+261.24%

$6.43

Potential upside vs current price

DCF Value-108.70%

-$0.15

Potential downside vs current price

Allogene Therapeutics, Inc.